Alphatec (ATEC) Q2 2026 Earnings Call Transcript
Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.
How this was made
The 30-second read
Why it matters
Traders can update models around raised FY adjusted EBITDA guidance, continued FCF positivity, and the key driver debate: utilization and adoption are strong, but biologics attachment stabilization is limiting revenue per case.
Market read
ATEC’s call combines strong utilization/adoption metrics with a guidance change (higher adjusted EBITDA) and a specific operational constraint (biologics attachment not improving).
What to watch
Free cash flow was only $1M in the quarter despite positive trailing-12-month FCF, and management explicitly flagged disappointment in biologics attachment, which could cap upside if it fails to re-accelerate.
Background
The article is a transcript-style summary of Alphatec’s Q2 2026 earnings call, covering operating KPIs, cash flow, and full-year guidance.
Ticker impact
Alphatec reported Q2 2026 revenue of $214M (+15% YoY), raised FY adjusted EBITDA guidance to about $140M, and reaffirmed FY revenue guidance near $882M.
Moderate positive bias for the next few sessions as raised FY adjusted EBITDA guidance and continued FCF positivity offset concerns about biologics attachment and revenue per case softness.
The article includes multiple new quantitative datapoints (Q2 results, raised EBITDA guidance, FCF trajectory, EOS Insight adoption) plus a specific management explanation for revenue per case decline tied to biologics attachment stabilization.
Market effects
Reinforces demand signals for spine procedural ecosystems and informatics add-ons (EOS Insight), potentially supporting sentiment toward medical device adoption models.
International expansion commentary (Japan, Australia, New Zealand) may support broader geographic growth expectations for spine procedure platforms.
If EOS Insight penetration scales, it could strengthen the narrative for global recurring revenue streams in spine imaging and alignment workflows.
Counterpoint
Revenue per case declined 2.7% YoY due to biologics attachment and international mix, suggesting growth quality may be less favorable than headline revenue growth implies.
Key entities
- companyAlphatec Holdings
Spine procedural ecosystem company reporting Q2 2026 results and guidance updates, including raised FY adjusted EBITDA.
- personPatrick Miles
CEO who discussed biologics attachment disappointment and EOS Insight infancy/predictive analytics potential.
- personJ. Todd Koning
CFO who explained margin and cash flow drivers and the biologics attach rate stabilization impact.
